Evoke Pharma (EVOK) Short Interest Ratio & Short Volume $4.31 +0.14 (+3.36%) As of 03:59 PM Eastern Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Evoke Pharma Short Interest DataEvoke Pharma (EVOK) has a short interest of 35,800 shares, representing 2.52% of the float (the number of shares available for trading by the public). This marks a -19.37% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 11,661 shares to cover all short positions.Current Short Interest35,800 sharesPrevious Short Interest44,400 sharesChange Vs. Previous Month-19.37%Dollar Volume Sold Short$158,236.00Short Interest Ratio0.1 Days to CoverLast Record DateDecember 31, 2024Outstanding Shares1,486,000 sharesFloat Size1,420,000 sharesShort Percent of Float2.52%Today's Trading Volume12,692 sharesAverage Trading Volume11,661 sharesToday's Volume Vs. Average109% Short Selling Evoke Pharma? Sign up to receive the latest short interest report for Evoke Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartEVOK Short Interest Over TimeEVOK Days to Cover Over TimeEVOK Percentage of Float Shorted Over Time Evoke Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 12/31/202435,800 shares $158,236.00 -19.4%2.5%0.1 $4.42 12/15/202444,400 shares $209,124.00 +76.9%3.1%0.1 $4.71 11/30/202425,100 shares $111,193.00 +47.7%1.9%0.1 $4.43 11/15/202417,000 shares $77,860.00 -83.2%1.3%0 $4.58 10/31/2024101,000 shares $590,850.00 +288.5%7.4%0.2 $5.85 10/15/202426,000 shares $132,860.00 -72.3%3.5%0.4 $5.11 Get the Latest News and Ratings for EVOK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter. 9/30/202493,900 shares $446,964.00 +43.1%12.5%1.3 $4.76 9/15/202465,600 shares $282,736.00 -15.3%8.8%1 $4.31 8/31/202477,400 shares $332,046.00 +2,176.5%10.4%1.3 $4.29 8/15/20243,400 shares $18,972.00 +61.9%0.5%0.1 $5.58 7/31/20242,100 shares $10,248.84 -78.6%0.3%0.6 $4.88 7/15/20249,800 shares $5,782.01 -13.3%0.1%0.4 $0.59 6/30/202411,300 shares $5,977.70 -54.4%0.2%0.4 $0.53 6/15/202424,800 shares $11,703.12 +40.1%0.3%0.9 $0.47 5/31/202417,700 shares $8,407.50 -56.5%0.2%0.5 $0.48 5/15/202440,700 shares $19,067.95 +6.0%0.6%1.2 $0.47 4/30/202438,400 shares $17,587.20 +4.9%0.6%1 $0.46 4/15/202436,600 shares $17,392.32 -31.5%0.5%0.9 $0.48 3/31/202453,400 shares $32,574.00 -25.9%0.8%0.9 $0.61 3/15/202472,100 shares $44,702.00 +21.8%1.1%1.2 $0.62 2/29/202459,200 shares $39,184.48 -73.1%0.7%1.1 $0.66 2/15/2024219,800 shares $153,860.00 -46.1%2.7%4.3 $0.70 1/31/2024407,900 shares $277,372.00 +419.0%12.5%9.1 $0.68 1/15/202478,600 shares $58,950.00 +83.2%2.4%2.2 $0.75 12/31/202342,900 shares $45,057.87 +371.4%1.3%3.4 $1.05 12/15/20239,100 shares $10,920.00 -43.8%0.3%0.6 $1.20 11/30/202316,200 shares $21,019.50 -28.0%0.5%1.2 $1.30 11/15/202322,500 shares $28,575.00 +54.1%0.7%1.8 $1.27 10/31/202314,600 shares $16,936.00 -51.8%0.5%1.1 $1.16 10/15/202330,300 shares $38,484.03 +41.6%0.9%2 $1.27 9/30/202321,400 shares $29,532.00 +20.9%0.7%1.4 $1.38 9/15/202317,700 shares $20,532.00 +391.7%0.5%1.4 $1.16 8/31/20233,600 shares $4,467.60 -76.9%0.1%0.1 $1.24 8/15/202315,600 shares $20,280.00 +136.4%0.5%0.6 $1.30 7/31/20236,600 shares $10,692.00 +1.5%0.2%0.2 $1.62 7/15/20236,500 shares $11,051.30 -57.0%0.2%0.2 $1.70 6/30/202315,100 shares $24,764.00 -65.8%0.5%0.5 $1.64 6/15/202344,100 shares $73,232.46 +390.0%1.4%1.4 $1.66 5/31/20239,000 shares $14,670.00 -65.5%0.3%0.4 $1.63 5/15/202326,100 shares $50,265.99 +107.1%0.8%1.5 $1.93 4/30/202312,600 shares $23,640.12 +12.5%0.4%0.7 $1.88 4/15/202311,200 shares $21,728.00 -7.4%0.3%0.4 $1.94 3/31/202312,100 shares $22,990.00 -67.5%0.4%0.4 $1.90 3/15/202337,200 shares $122,760.00 +42.5%1.1%1 $3.30 2/28/202326,100 shares $75,951.00 +54.4%0.8%0.6 $2.91 2/15/202316,900 shares $47,827.00 -71.1%0.5%0.4 $2.83 1/31/202358,500 shares $236,340.00 +61.2%1.8%1.5 $4.04 1/15/202336,300 shares $111,804.00 -33.9%1.1%1.2 $3.08 12/30/202254,900 shares $147,132.00 +42.2%1.7%2.2 $2.68 12/15/202238,600 shares $72,954.00 +27.4%1.2%1.8 $1.89 11/30/202230,300 shares $45,450.00 +14.8%0.9%1.6 $1.50 11/15/202226,400 shares $44,352.00 +7.8%0.8%1.9 $1.68 10/31/202224,500 shares $42,385.00 +12.9%0.8%1.3 $1.73 10/15/202221,700 shares $42,482.09 -18.4%0.7%0.7 $1.96 9/30/202226,600 shares $49,742.00 -25.7%0.8%0.8 $1.87 9/15/202235,800 shares $80,550.00 +26.1%1.1%0.8 $2.25 8/31/202228,400 shares $76,680.00 -52.5%N/A0 $2.70 8/15/202259,800 shares $163,852.00 +76.9%N/A0.1 $2.74 7/31/202233,800 shares $103,090.00 -44.7%N/A0 $3.05 7/15/202261,100 shares $189,410.00 -61.9%N/A0.1 $3.10 6/30/2022160,400 shares $519,696.00 +83.1%N/A0.1 $3.24 6/15/202287,600 shares $262,800.00 +47.5%N/A0.1 $3.00 5/31/202259,400 shares $159,786.00 +70.7%N/A0.1 $2.69 5/15/202234,800 shares $113,879.52 -98.0%N/A0.1 $3.27 4/30/20221,770,000 shares $831,900.00 +1,906.8%5.7%0.4 $0.47 4/15/202288,200 shares $33,780.60 -37.5%0.3%0.8 $0.38 3/31/2022141,200 shares $69,894.00 -19.0%N/A0 $0.50 3/15/2022174,400 shares $80,224.00 +4.8%0.6%1.2 $0.46 2/28/2022166,400 shares $106,163.20 -23.3%0.5%0.6 $0.64 2/15/2022217,000 shares $145,932.50 -6.9%0.7%0.7 $0.67 1/31/2022233,000 shares $127,031.60 +70.6%0.7%0.7 $0.55 1/15/2022136,600 shares $69,474.76 -0.9%N/A0.4 $0.51 12/31/2021137,800 shares $75,790.00 -25.1%0.4%0.4 $0.55 12/15/2021184,000 shares $115,000.00 -39.3%0.6%0.6 $0.63 11/30/2021303,300 shares $230,477.67 -28.6%1.0%1.3 $0.76 11/15/2021424,500 shares $424,500.00 -16.8%1.3%2.4 $1.00 10/29/2021509,900 shares $627,177.00 -12.0%1.6%1 $1.23 10/15/2021579,100 shares $799,158.00 +4.3%1.8%1.2 $1.38 9/30/2021555,300 shares $721,890.00 -2.0%1.8%1.1 $1.30 9/15/2021566,500 shares $628,815.00 -13.3%1.8%1.1 $1.11 8/31/2021653,200 shares $764,244.00 +42.0%2.1%1.3 $1.17 8/13/2021460,000 shares $616,400.00 -13.9%1.5%0.8 $1.34 7/30/2021534,500 shares $598,640.00 -28.7%1.7%2.1 $1.12 7/15/2021749,900 shares $922,377.00 +33.8%2.4%2.7 $1.23 6/30/2021560,300 shares $767,611.00 -31.5%1.8%1.8 $1.37 6/15/2021818,400 shares $1.10 million -17.2%2.6%2.3 $1.35 5/28/2021988,100 shares $1.22 million -14.8%3.4%1.9 $1.23 5/14/20211,160,000 shares $1.32 million -7.2%N/A2.3 $1.14 4/30/20211,250,000 shares $2.13 million +14.7%N/A1.8 $1.70 4/15/20211,090,000 shares $1.85 million -2.7%N/A0 $1.70 3/31/20211,120,000 shares $1.98 million +46.7%N/A1.4 $1.77 3/15/2021763,500 shares $1.87 million +4.4%N/A1 $2.45 2/26/2021731,700 shares $2.28 million +48.2%N/A1.2 $3.11 2/12/2021493,800 shares $1.70 million +26.8%N/A0.8 $3.45 1/29/2021389,400 shares $981,288.00 -55.2%N/A0.7 $2.52 1/15/2021869,300 shares $2.53 million +56.4%N/A2.5 $2.91 12/31/2020555,800 shares $1.50 million +18.4%N/A2.3 $2.69 12/15/2020469,300 shares $1.38 million +37.5%N/A2 $2.95 11/30/2020341,300 shares $1.04 million -4.3%N/A1.5 $3.04 11/15/2020356,800 shares $1.32 million +0.2%1.5%1.4 $3.71 10/30/2020356,100 shares $1.42 million -38.6%1.6%1.3 $3.99 10/15/2020580,200 shares $2.79 million +8.5%2.5%1.6 $4.81 9/30/2020534,800 shares $2.51 million -11.4%2.3%1.3 $4.69 9/15/2020603,300 shares $2.95 million -2.2%2.6%1.1 $4.89 8/31/2020617,100 shares $2.76 million -10.4%2.7%0.4 $4.47 8/14/2020688,500 shares $3.92 million +14.4%3.0%0.4 $5.70 7/31/2020601,700 shares $2.22 million -31.5%2.6%0.4 $3.69 7/15/2020878,000 shares $3.19 million -28.0%4.0%0.6 $3.63 6/30/20201,220,000 shares $4.25 million +293.9%5.6%0.8 $3.48 6/15/2020309,700 shares $740,183.00 +13.8%1.4%0.2 $2.39 5/29/2020272,200 shares $672,334.00 +120.4%1.2%0.7 $2.47 5/15/2020123,500 shares $174,135.00 +27.5%0.6%0.4 $1.41 4/30/202096,900 shares $128,877.00 -4.0%0.5%0.6 $1.33 4/15/2020100,900 shares $125,116.00 -25.1%0.5%0.6 $1.24 3/31/2020134,700 shares $157,599.00 -42.9%0.6%0.8 $1.17 3/13/2020235,900 shares $259,490.00 -7.9%1.1%1.2 $1.10 2/28/2020256,100 shares $225,368.00 -25.7%1.2%1.2 $0.88 2/14/2020344,500 shares $413,400.00 -12.2%1.6%1.4 $1.20 1/31/2020392,400 shares $537,588.00 -30.0%1.9%1.3 $1.37 1/15/2020560,200 shares $795,484.00 +4.9%2.7%1.9 $1.42 EVOK Short Interest - Frequently Asked Questions What is Evoke Pharma's current short interest? Short interest is the volume of Evoke Pharma shares that have been sold short but have not yet been closed out or covered. As of December 31st, traders have sold 35,800 shares of EVOK short. 2.52% of Evoke Pharma's shares are currently sold short. Learn More on Evoke Pharma's current short interest. What is a good short interest percentage for Evoke Pharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.52% of Evoke Pharma's floating shares are currently sold short. Is Evoke Pharma's short interest increasing or decreasing? Evoke Pharma saw a decline in short interest in the month of December. As of December 31st, there was short interest totaling 35,800 shares, a decline of 19.4% from the previous total of 44,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Evoke Pharma's float size? Evoke Pharma currently has issued a total of 1,486,000 shares. Some of Evoke Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Evoke Pharma currently has a public float of 1,420,000 shares. How does Evoke Pharma's short interest compare to its competitors? 2.52% of Evoke Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Evoke Pharma: Equillium, Inc. (0.59%), DURECT Co. (3.05%), Lipocine Inc. (0.93%), Natural Alternatives International, Inc. (0.09%), Enlivex Therapeutics Ltd. (0.58%), Pluri Inc. (0.61%), NextCure, Inc. (0.45%), IN8bio, Inc. (0.84%), GeoVax Labs, Inc. (3.96%), Cocrystal Pharma, Inc. (0.40%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.83 billion), Charter Communications, Inc. ($3.77 billion), Reddit, Inc. ($2.98 billion), The Kroger Co. ($2.97 billion), International Paper ($2.64 billion), SoFi Technologies, Inc. ($1.99 billion), Rivian Automotive, Inc. ($1.93 billion), Onsemi ($1.81 billion), SoundHound AI, Inc. ($1.59 billion), and Moderna, Inc. ($1.57 billion). View all of the most shorted stocks. What does it mean to sell short Evoke Pharma stock? Short selling EVOK is an investing strategy that aims to generate trading profit from Evoke Pharma as its price is falling. EVOK shares are trading up $0.14 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Evoke Pharma? A short squeeze for Evoke Pharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of EVOK, which in turn drives the price of the stock up even further. How often is Evoke Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EVOK, twice per month. The most recent reporting period available is December, 31 2024. More Short Interest Resources from MarketBeat Related Companies EQ Short Interest Data DRRX Short Interest Data LPCN Short Interest Data NAII Short Interest Data ENLV Short Interest Data PLUR Short Interest Data NXTC Short Interest Data INAB Short Interest Data GOVX Short Interest Data COCP Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EVOK) was last updated on 1/14/2025 by MarketBeat.com Staff From Our PartnersStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in JanuaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
